Edition:
United States

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

12.35USD
3:59pm EST
Change (% chg)

$0.24 (+1.98%)
Prev Close
$12.11
Open
$12.10
Day's High
$12.45
Day's Low
$11.80
Volume
39,233
Avg. Vol
55,370
52-wk High
$24.35
52-wk Low
$10.30

Chart for

About

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments... (more)

Overall

Beta: --
Market Cap(Mil.): $318.45
Shares Outstanding(Mil.): 26.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.18 15.80
EPS (TTM): -- -- --
ROI: -- 15.02 12.07
ROE: -- 16.37 16.02

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

Nov 08 2017

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

Oct 05 2017

BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing

* Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing Source text: [http://bit.ly/2hAgfq3] Further company coverage:

Sep 29 2017

BRIEF-Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​

* Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​ Source text for Eikon: Further company coverage:

Sep 11 2017

BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

* Syros receives fda orphan drug designation for SY-1425 for treatment of AML

Aug 21 2017

BRIEF-Syros Pharmaceuticals Q2 loss per share $0.52

* Syros reports second quarter 2017 financial results and highlights accomplishments and upcoming milestones

Aug 09 2017

BRIEF-Syros publishes foundational data supporting phase 2 clinical trial

* Syros publishes foundational data supporting ongoing phase 2 clinical trial of SY-1425 for genomically defined AML and MDS patients

Jul 21 2017

BRIEF-Syros announces preclinical data on SY-1425

* Syros presents data at EHA supporting potential of SY-1425, its first-in-class selective RARα agonist, in genomically defined AML and MDS patients

Jun 23 2017

Earnings vs. Estimates